1. Introduction {#sec1-medicines-06-00108}
===============

Acute kidney injury (AKI), a heterogeneous clinical syndrome, is a significant health problem worldwide with a steady increase in the incidence \[[@B1-medicines-06-00108]\]. The burden of AKI is 13.3 million cases a year globally and is associated with high mortality at 1.7 million deaths annually \[[@B2-medicines-06-00108],[@B3-medicines-06-00108],[@B4-medicines-06-00108]\]. Survivors of AKI are subsequently at higher risk for cardiovascular events, chronic kidney disease (CKD), and progression to end-stage kidney disease (ESKD) \[[@B5-medicines-06-00108]\]. The number of hospitalizations from AKI is steeply rising as evidenced by the national inpatient sample data in the United States between 2000 onwards with close to 3.9 million admissions in 2014 \[[@B6-medicines-06-00108]\].

There is a steady and gradual annual global increase in the number of cardiac transplantations ever since the first successful transplantation in 1967 \[[@B7-medicines-06-00108]\]. The cardiac transplantation has evolved over the years and ever since the introduction of the newer immunosuppressive calcineurin inhibitors, it has evolved into a life-sustaining treatment of choice for the many end-stage heart disease patients \[[@B8-medicines-06-00108],[@B9-medicines-06-00108],[@B10-medicines-06-00108],[@B11-medicines-06-00108],[@B12-medicines-06-00108],[@B13-medicines-06-00108],[@B14-medicines-06-00108]\]. However, AKI after cardiac transplantation is a common complication, which can lead to subsequent progressive CKD and ESKD requiring dialysis post cardiac transplantation \[[@B15-medicines-06-00108],[@B16-medicines-06-00108],[@B17-medicines-06-00108]\]. Despite tremendous advances in the field of cardiac transplant medicine and surgical techniques, there is a paucity of data on the incidence, associated risk factors, and mortality risk of AKI in patients undergoing cardiac transplantation. In addition, the incidence of AKI among patients undergoing cardiac transplantation is not uniformly described among studies, ranging from 40% to 70% \[[@B18-medicines-06-00108],[@B19-medicines-06-00108],[@B20-medicines-06-00108],[@B21-medicines-06-00108],[@B22-medicines-06-00108],[@B23-medicines-06-00108]\].

Thus, this meta-analysis aims to assess the incidence of AKI and mortality risk of AKI in adult patients after cardiac transplantation.

2. Methods {#sec2-medicines-06-00108}
==========

2.1. Search Strategy {#sec2dot1-medicines-06-00108}
--------------------

The protocol for this study is registered with PROSPERO (International Prospective Register of Systematic Reviews no. CRD42019134577). We conducted a systematic literature review of Ovid MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews until June 2019 to evaluate the incidence of AKI and mortality risk of AKI in adult patients undergoing cardiac transplantation. Independent reviewers (C.T. and P.L.) conducted a systematic literature search using a search strategy that incorporated the search terms "heart" OR "cardiac" AND "transplant" OR "transplantation" AND "acute renal failure." OR "acute kidney injury". Additional details on the search approach employed for each database is provided in [Supplementary Materials, Supplementary Data 1](#app1-medicines-06-00108){ref-type="app"}. A manual search for conceivably related articles utilizing references of the included studies was additionally performed. No language restriction was implemented. This systematic review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) \[[@B24-medicines-06-00108]\].

2.2. Study Selection {#sec2dot2-medicines-06-00108}
--------------------

Studies were eligible for this meta-analysis if the studies were clinical trials or observational studies that had data on the incidence of AKI (using standard AKI definitions including Kidney Disease: Improving Global Outcomes (KDIGO) classifications \[[@B25-medicines-06-00108]\], Acute Kidney Injury Network (AKIN) \[[@B26-medicines-06-00108]\], Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) \[[@B27-medicines-06-00108]\]), and AKI requiring renal replacement therapy (RRT), and mortality risk of AKI in patients (aged 18 years and older) undergoing cardiac transplantation. Included studies had to have the data to assess the incidence or mortality risk of AKI. Retrieved studies were individually evaluated for eligibility by the two investigators (C.T. and P.L.). Conflicts were discussed and solved by consensus or by a third reviewer (W.C.).

A structured information collecting form was utilized to gather the following information from each included study including title of the article, name of investigators, year of the study, country where the study was conducted, publication year, incidence of AKI, definition of AKI, risk factor for AKI, and mortality risk of AKI in patients undergoing cardiac transplantation.

2.3. Statistical Analysis {#sec2dot3-medicines-06-00108}
-------------------------

We used comprehensive meta-analysis software version 3.3.070 (Biostat Inc, United States) for all analyses. Pooled AKI incidence and mortality risk of included studies were incorporated by the generic inverse variance method of DerSimonian-Laird, which indicated the weight of each study depending on its variance \[[@B28-medicines-06-00108]\]. Due to the likelihood of inter-observation variance, we utilized a random-effects model for meta-analyses of the incidence and mortality risk of AKI among patients undergoing cardiac transplantation. Statistical heterogeneity of studies was evaluated by the Cochran's Q test (statistically significant as *p* \< 0.05) and the *I*^2^ statistic (≤ 25% represents insignificant heterogeneity, 26% to 50% represents low heterogeneity, 51% to 75% represents moderate heterogeneity, and ≥ 75 % represents high heterogeneity) \[[@B29-medicines-06-00108]\]. Publication bias was assessed by both the Egger test and the funnel plot \[[@B30-medicines-06-00108]\].

3. Results {#sec3-medicines-06-00108}
==========

A total of 4252 conceivably suitable articles were initially identified with our search strategy. Subsequently, 1678 articles were excluded due to being duplicates, and we also excluded 2367 articles that were either in-vitro studies, animal studies, pediatric patient population, correspondences, review articles, or case reports. Thus, 207 articles were entered for full-length article review. Subsequently, 94 studies were excluded as these studies did not have data on the incidence or mortality of AKI, 77 articles were additionally excluded because they were not observational studies or clinical trials, and 9 studies were excluded because they did not utilize a standard AKI definition or did not describe the incidence of AKI requiring RRT. Finally, 27 cohort studies \[[@B8-medicines-06-00108],[@B18-medicines-06-00108],[@B19-medicines-06-00108],[@B20-medicines-06-00108],[@B31-medicines-06-00108],[@B32-medicines-06-00108],[@B33-medicines-06-00108],[@B34-medicines-06-00108],[@B35-medicines-06-00108]\] with 137,201 patients undergoing cardiac transplantation were identified. The flowchart of this study is shown in [Figure 1](#medicines-06-00108-f001){ref-type="fig"}. The characteristics of the included studies are shown in [Table 1](#medicines-06-00108-t001){ref-type="table"}.

3.1. Incidence of AKI Among Patients Undergoing Cardiac Transplantation {#sec3dot1-medicines-06-00108}
-----------------------------------------------------------------------

Pooled estimated incidence of AKI was 47.1% (95% confidence intervals (CI): 37.6--56.7%, *I*^2^ = 97%, [Figure 2](#medicines-06-00108-f002){ref-type="fig"}) and severe AKI requiring RRT among patients undergoing cardiac transplantation was 11.8% (95% CI: 7.2%--18.8%, *I*^2^ = 98%, [Figure 3](#medicines-06-00108-f003){ref-type="fig"}). Subgroup analyses were conducted according to AKI definitions. The pooled incidence of AKI by RIFLE, AKIN, and KDIGO criteria were 35.3% (95% CI: 20.5--53.5%, *I*^2^ = 95%), by AKIN criteria: 29.9% (95% CI: 16.3--48.3%, *I*^2^ = 92%), and KGDIGO criteria: 62.8% (95% CI: 49.2--74.7%, *I*^2^ = 96%).

Subgroup analyses based on year of study (before and after the year 2015) were performed to assess if there was any difference in the incidence of AKI among studies from the recent years vs the former years. The pooled estimated incidence rates of AKI and AKI requiring RRT before the year of 2015 were 33.8% (95% CI: 18.8--52.9%, *I*^2^ = 96%) and 9.4% (95% CI: 5.6--15.3%, *I*^2^ = 61%), respectively. The pooled estimated incidence rates of AKI and AKI requiring RRT after the year of 2015 were 49.4% (95% CI: 35.7--63.2%, *I*^2^ = 97%) and 12.3% (95% CI: 7.2--20.1%, *I*^2^ = 98%), respectively.

3.2. Impact of AKI on Mortality among Patients Undergoing Cardiac Transplantation {#sec3dot2-medicines-06-00108}
---------------------------------------------------------------------------------

Mortality risk associated with AKI among patients undergoing cardiac transplantation is summarized in [Table 2](#medicines-06-00108-t002){ref-type="table"}. Pooled ORs of hospital mortality and/or 90-day mortality among patients undergoing cardiac transplantation with AKI and severe AKI requiring RRT were 3.46 (95% CI, 2.40--4.97, *I*^2^ = 0%, [Figure 4](#medicines-06-00108-f004){ref-type="fig"}A) and 13.05 (95% CI, 6.89--24.70, *I*^2^ = 75%, [Figure 4](#medicines-06-00108-f004){ref-type="fig"}B), respectively. When the analysis was restricted to only studies with confounder-adjusted analysis, the higher hospital mortality was still significant in patients undergoing cardiac transplantation with AKI pooled OR of 4.10 (95% CI, 2.57--6.54, *I*^2^ = 0%, [Supplementary Materials, Figure S1](#app1-medicines-06-00108){ref-type="app"}) and severe AKI requiring RRT with pooled OR of 8.93 (95% CI, 3.48--22.92, *I*^2^ = 57%, [Supplementary Materials, Figure S2](#app1-medicines-06-00108){ref-type="app"}).

The pooled ORs of 1-year mortality among patients undergoing cardiac transplantation with AKI were 2.26 (95% CI, 1.56--3.26, *I*^2^ = 0%, [Supplementary Materials, Figure S3](#app1-medicines-06-00108){ref-type="app"}) and AKI requiring RRT were 3.89 (95% CI, 2.49--6.08, *I*^2^ = 17%, [Supplementary Materials, Figure S4](#app1-medicines-06-00108){ref-type="app"}). When the meta-analysis was restricted to studies with confounder-adjusted analysis, the higher 1-year mortality was still significant in patients undergoing cardiac transplantation with AKI (pooled ORs of 3.11 (95% CI, 1.66--5.82, *I*^2^ = 0%, [Supplementary Materials, Figure S5](#app1-medicines-06-00108){ref-type="app"})) and AKI requiring RRT with pooled ORs of 4.06 (95% CI, 1.69--9.75, *I*^2^ = 36%, [Supplementary Materials, Figure S6](#app1-medicines-06-00108){ref-type="app"}). Meta-regression demonstrated that year of the study was not correlated with the risks of hospital mortality (and/or 90-day mortality) (*p* = 0.93) or 1-year mortality (*p* = 0.44) among patients undergoing cardiac transplantation with AKI.

3.3. Evaluation for Publication Bias {#sec3dot3-medicines-06-00108}
------------------------------------

Funnel plots ([Supplementary Materials, Figures S7 and S8](#app1-medicines-06-00108){ref-type="app"}) and Egger's regression asymmetry tests were used to evaluate publication bias in meta-analyses assessing hospital mortality (and/or 90-day mortality) and 1-year mortality of AKI among patients undergoing cardiac transplantation. We found no publication bias for analyses assessing the hospital mortality (and/or 90-day mortality; *p* = 0.46) and 1-year mortality of AKI among patients undergoing cardiac transplantation (*p* = 0.24).

4. Discussion {#sec4-medicines-06-00108}
=============

In this study, we revealed that AKI and AKI requiring RRT among patients undergoing cardiac transplantation are fairly common (47% and 12%, respectively). In addition, the incidence of AKI and severe AKI requiring RRT have been increasing in recent years. AKI post cardiac transplantation is associated with increased short term (3.5-fold) and 1-year (2.3-fold) mortality. Despite advances in transplant medicine, meta-regression showed that the risks of hospital mortality (and/or 90-day mortality) or 1-year mortality among patients undergoing cardiac transplantation with AKI has not improved over time.

As there are currently no effective targeted pharmacotherapies available for AKI, prevention of AKI and early identification of patients at risk for AKI among patients undergoing heart transplantation may potentially play an important role in improving patient outcomes, given high short- and long-term mortality risks associated with AKI after cardiac transplantation. Reported risk factors for AKI in patients undergoing cardiac transplantation are shown in [Table 3](#medicines-06-00108-t003){ref-type="table"}. Preoperative risk factors including chronic kidney disease (CKD) \[[@B8-medicines-06-00108],[@B19-medicines-06-00108],[@B36-medicines-06-00108],[@B43-medicines-06-00108],[@B51-medicines-06-00108]\], diabetes mellitus (DM) \[[@B36-medicines-06-00108],[@B43-medicines-06-00108]\], and older age \[[@B19-medicines-06-00108],[@B41-medicines-06-00108],[@B52-medicines-06-00108]\]. were consistently demonstrated as associated risk factors for AKI in patients after cardiac transplantation. Perioperative and post risk factors for AKI among patients undergoing cardiac transplantation included increased cardiopulmonary bypass and surgery time \[[@B20-medicines-06-00108],[@B36-medicines-06-00108],[@B50-medicines-06-00108]\], supratherapeutic calcineurin inhibitor concentration \[[@B38-medicines-06-00108],[@B41-medicines-06-00108],[@B50-medicines-06-00108]\], post-operative bleeding, anemia, and blood transfusion \[[@B18-medicines-06-00108],[@B20-medicines-06-00108],[@B39-medicines-06-00108],[@B52-medicines-06-00108]\], postoperative RV failure and the need for a right ventricular assist device (RVAD) after heart transplant \[[@B8-medicines-06-00108],[@B23-medicines-06-00108]\], duration of mechanical ventilation and the need for venoarterial extra-corporal membrane oxygenation (VA ECMO) after heart transplant \[[@B23-medicines-06-00108]\].

At the patient level, the primary indications for cardiac transplantation are nonischemic cardiomyopathy (53%) and ischemic cardiomyopathy (38%) \[[@B54-medicines-06-00108]\]. These patients generally carry significant co-morbidities, such as diabetes, hypertension, and congestive heart failure (right heart failure and reduced pulmonary artery pulsatility index prior to heart transplantation) that predispose them to develop AKI \[[@B18-medicines-06-00108]\]. At the peri-operative level, AKI among patients undergoing cardiac transplantation has been reportedly associated with duration of the cardiopulmonary bypass (CPB), prolonged mechanical ventilation, ischemic reperfusion injury, and anemia \[[@B8-medicines-06-00108],[@B20-medicines-06-00108],[@B38-medicines-06-00108],[@B41-medicines-06-00108],[@B53-medicines-06-00108],[@B55-medicines-06-00108],[@B56-medicines-06-00108]\]. The use of CPB has been associated with AKI risk, which is supported by a meta-analysis from Pickering et al. \[[@B57-medicines-06-00108]\]. Moreover, CPB duration, the use of mannitol and furosemide during CPB, and urine output during CPB can influence the incidence of AKI \[[@B58-medicines-06-00108]\].

There are some limitations that are worth noting here. Most included studies used serum creatinine as a criterion for AKI, which might underestimate the incidence of AKI. Moreover, our meta-analysis primarily depends on observational studies given the lack of clinical trials on this particular topic. Thus, it is difficult to conclude a causal relationship based on data from observation studies. Nonetheless, more in-depth data from population-based studies or clinical trials on AKI prevention among patients receiving cardiac transplantation is practical and encouraged. For instance, a recent single-center prospective cohort study has demonstrated some benefit of utilizing novel biomarkers in predicting post-operative AKI after cardiac surgery (n = 23) \[[@B59-medicines-06-00108]\]. A larger cohort is currently under investigation. Lastly, AKI is a known independent risk factor for the development of CKD \[[@B60-medicines-06-00108],[@B61-medicines-06-00108],[@B62-medicines-06-00108]\] and one of the important adverse effects of calcineurin inhibitors among cardiac transplant patients is the development of CKD leading to ESKD. Future studies are required if optimizing/modifying the immunosuppressive regimen among cardiac transplant patients with AKI can help prevent CKD and delay CKD progression.

In summary, we revealed that almost half of patients undergoing cardiac transplantation developed AKI. Severe AKI requiring RRT is as high as 12%. AKI and AKI requiring RRT after cardiac transplantation are associated with increased risk of 90-day mortality and 1-year mortality. We also emphasized that AKI requiring RRT is a poor prognostic predictor as these patients have a 13-fold increased risk of dying within 90 days post-transplant.

The following are available online at <https://www.mdpi.com/2305-6320/6/4/108/s1>, Figure S1. Forest plots of the included studies assessing the pooled OR of hospital mortality among patients undergoing cardiac transplantation with AKI limited to studies with confounder-adjusted analysis, Figure S2. Forest plots of the included studies assessing the pooled OR of hospital mortality among patients undergoing cardiac transplantation with AKI requiring RRT limited to studies with confounder-adjusted analysis, Figure S3. Forest plots of the included studies assessing the pooled OR of 1-year mortality among patients undergoing cardiac transplantation with AKI, Figure S4. Forest plots of the included studies assessing the pooled OR of 1-year mortality among patients undergoing cardiac transplantation with AKI requiring RRT, Figure S5. Forest plots of the included studies assessing the pooled OR of 1-year mortality among patients undergoing cardiac transplantation with AKI limited to studies with confounder-adjusted analysis, Figure S6. Forest plots of the included studies assessing the pooled OR of 1-year mortality among patients undergoing cardiac transplantation with AKI requiring RRT limited to studies with confounder-adjusted analysis, Figure S7. Funnel plot evaluating for publication bias evaluating hospital mortality (and/or 90-day mortality) of AKI among patients undergoing cardiac transplantation, Figure S8. Funnel plot evaluating for publication bias evaluating 1-year mortality of AKI among patients undergoing cardiac transplantation.
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medicines-06-00108-t001_Table 1

###### 

Included studies in this systematic review of AKI incidence and mortality in patients undergoing cardiac transplantation. \[[@B8-medicines-06-00108],[@B18-medicines-06-00108],[@B19-medicines-06-00108],[@B20-medicines-06-00108],[@B31-medicines-06-00108],[@B32-medicines-06-00108],[@B33-medicines-06-00108],[@B34-medicines-06-00108],[@B35-medicines-06-00108]\].

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                           Year   Country           Patient Population                                                                            Number    Definition of AKI   Incidence of AKI           Mortality
  --------------------------------------------------------------- ------ ----------------- --------------------------------------------------------------------------------------------- --------- ------------------- -------------------------- ----------------------------
  Ouseph et al. \[[@B31-medicines-06-00108]\]                     1998   USA               Orthotopic heart transplant                                                                   52        RRT                 RRT, 8/52 (15.4%)          1-year mortality\
                                                                                                                                                                                                                                                  RRT, 5/8 (62.5%)

  Canver et al. \[[@B32-medicines-06-00108]\]                     2000   USA               Orthotopic heart transplant                                                                   199       RRT                 RRT, 9/199 (4.5%)          RRT, 4/9 (44.4%)

  Stevens et al. \[[@B33-medicines-06-00108]\]                    2004   Canada            Heart transplant                                                                              56        CRRT                CRRT, 6/56 (10.71%)        RRT, 0/6 (0%)

  Wyatt et al. \[[@B34-medicines-06-00108]\]                      2004   USA               Heart transplant in New York State                                                            141       RRT                 RRT, 15/141 (10.6%)        N/A

  Odim et al. \[[@B35-medicines-06-00108]\]                       2005   USA               Orthotopic heart transplant                                                                   627       RRT                 RRT, 80/627 (12.8%)        Hospital mortality\
                                                                                                                                                                                                                                                  RRT, 33/80 (41.3%)

  Boyle et al. \[[@B36-medicines-06-00108]\]                      2006   USA               Orthotopic heart transplant                                                                   756       RRT                 RRT, 44/756 (5.8%)         Hospital mortality\
                                                                                                                                                                                                                                                  RRT, 22/44 (50%)\
                                                                                                                                                                                                                                                  30-day mortality\
                                                                                                                                                                                                                                                  RRT, 17/44 (38.6%)

  Escoresca Ortega et al. \[[@B37-medicines-06-00108]\]           2010   Spain             Heart transplant                                                                              54        RIFLE criteria      AKI, 38/54 (70.4%)\        AKI, 30/38 (78.94%)\
                                                                                                                                                                                                                       RRT, 15/54 (27.8%)         RRT, 7/15 (46.7%)

  Gude et al. \[[@B38-medicines-06-00108]\]                       2010   Norway            Orthotopic heart transplant                                                                   585       AKIN criteria       AKI, 145/585 (24.8%)\      30-day mortality\
                                                                                                                                                                                                                       RRT, 71/585 (12.1%)        RRT, 11/71 (15.5%)\
                                                                                                                                                                                                                                                  90-day mortality\
                                                                                                                                                                                                                                                  RRT, 15/71 (21.1%)

  De Santo et al. \[[@B39-medicines-06-00108]\]                   2011   Italy             Orthotopic heart transplant                                                                   307       RIFLE criteria      AKI, 43/307 (14.0%)\       Hospital mortality\
                                                                                                                                                                                                                       CVVH, 19/307 (6.2%)        AKI, 12/43 (27.9%)\
                                                                                                                                                                                                                                                  1-year mortality\
                                                                                                                                                                                                                                                  AKI, 12/43 (27.9%)

  Arnaoutakis et al. \[[@B40-medicines-06-00108]\]                2012   USA               LVAD-bridged heart transplant from UNOS data                                                  1312      RRT                 RRT, 106/1312 (8.1%)       90-day mortality\
                                                                                                                                                                                                                                                  RRT, 41/93 (44.1%)

  Türker et al. \[[@B41-medicines-06-00108]\]                     2013   Turkey            Heart transplant                                                                              44        RIFLE criteria      AKI, 27/44 (61.4%)\        AKI, 7/26 (26.9%)
                                                                                                                                                                                                                       RRT, 17/44 (38.6%)         

  Crudele et al. \[[@B42-medicines-06-00108]\]                    2013   Italy             Heart transplant                                                                              158       RIFLE criteria      AKI, 27/158 (17.1%)        AKI, 9/27 (33.3%)

  Knezevic et al. \[[@B43-medicines-06-00108]\]                   2014   Slovenia          Heart transplant                                                                              94        RRT                 RRT, 6/94 (6.4%)           N/A

  Gültekin et al. \[[@B44-medicines-06-00108]\]                   2015   Turkey            Orthotopic heart transplant                                                                   64        KDIGO criteria      AKI, 34/64 (53.1%)\        N/A
                                                                                                                                                                                                                       RRT, 25/64 (39.1%)         

  Fortrie et al. \[[@B8-medicines-06-00108]\]                     2016   The Netherlands   Heart transplant                                                                              531       KDIGO criteria      AKI, 405/531 (76.3%)\      Hospital mortality\
                                                                                                                                                                                                                       RRT, 25/531 (4.7%)         AKI, 28/405 (6.9%)\
                                                                                                                                                                                                                                                  RRT, 5/25 (20.0%)\
                                                                                                                                                                                                                                                  1-year mortality\
                                                                                                                                                                                                                                                  AKI, 41/405 (10.12%)\
                                                                                                                                                                                                                                                  RRT, 7/25 (28.0%)

  Tjahjono et al. \[[@B20-medicines-06-00108]\]                   2016   Australia         Orthotopic heart transplant                                                                   111       RIFLE criteria      AKI, 65/111 (58.6%)\       AKI, 15/65 (23.1%)
                                                                                                                                                                                                                       RRT, 38/111 (34.2%)        

  Schiferer et al. \[[@B45-medicines-06-00108]\]                  2016   Austria           Heart transplant                                                                              346       RIFLE criteria      AKI\                       1-year mortality\
                                                                                                                                                                                                                       RIFLE, 76/346 (22.0%)\     RIFLE AKI, 19/76 (25.00%)\
                                                                                                                                                                                                                       RRT, 54/346 (15.6%)        RRT, 20/54 (37.0%)

  Nadkarni et al. \[[@B46-medicines-06-00108]\]                   2017   USA               Orthotopic heart transplant from the Nationwide Inpatient Sample database during 2002--2013   130,143   RRT                 RRT, 2776/130,143 (2.1%)   N/A

  Giglio Canelhas de Abreu et al. \[[@B47-medicines-06-00108]\]   2017   Brazil            Heart transplant                                                                              103       AKIN criteria       AKI, 50/103 (48.5%)        AKI, 16/50 (32%)

  Sun et al. \[[@B48-medicines-06-00108]\]                        2018   USA               Patients with preexisting LVADs who underwent orthotopic heart transplantation                74        RIFLE criteria      AKI, 18/74 (24.3%)         N/A

  Romeo et al. \[[@B19-medicines-06-00108]\]                      2018   Argentina         Heart transplant                                                                              112       KDIGO criteria      AKI, 81/112 (72.3%)\       Hospital mortality\
                                                                                                                                                                                                                       RRT, 27/112 (24.1%)        AKI, 16/81 (19.8%)\
                                                                                                                                                                                                                                                  RRT, 14/27 (51.9%)\
                                                                                                                                                                                                                                                  1-year mortality\
                                                                                                                                                                                                                                                  AKI, 19/81 (23.5%)\
                                                                                                                                                                                                                                                  RRT, 16/27 (59.3%)

  Gašparović et al. \[[@B49-medicines-06-00108]\]                 2018   Croatia           Heart transplant                                                                              158       RRT                 RRT, 27/158 (17.1%)        3-month mortality\
                                                                                                                                                                                                                                                  RRT 17/27 (63.0%)

  Sikma et al. \[[@B50-medicines-06-00108]\]                      2018   The Netherlands   Heart transplant                                                                              110       KDIGO criteria      AKI, 63/110 (57.3%)\       N/A
                                                                                                                                                                                                                       RRT, 7/110 (6.4%)          

  Ivey-Miranda et al. \[[@B51-medicines-06-00108]\]               2018   Mexico            Heart transplant                                                                              106       RRT                 RRT, 21/106 (19.81%)       N/A

  Jahangirifard et al. \[[@B52-medicines-06-00108]\]              2018   Iran              Heart transplant                                                                              53        AKIN criteria       AKI, 10/53 (18.87%)        N/A

  Guven et al. \[[@B53-medicines-06-00108]\]                      2018   The Netherlands   Heart transplant                                                                              595       KDIGO criteria      AKI, 430/595 (72.3%)\      Hospital mortality\
                                                                                                                                                                                                                       RRT, 41/595 (6.9%)         AKI, 32/430 (7.4%)\
                                                                                                                                                                                                                                                  1-year mortality\
                                                                                                                                                                                                                                                  AKI, 43/430 (10.0%)\
                                                                                                                                                                                                                                                  RRT, 9/41 (22.0%)

  García-Gigorro et al. \[[@B18-medicines-06-00108]\]             2018   Spain             Heart transplant                                                                              310       KDIGO criteria      AKI, 125/310 (40.3%)\      Hospital mortality\
                                                                                                                                                                                                                       RRT, 32/310 (10.3%)        AKI, 20/125 (16%)\
                                                                                                                                                                                                                                                  RRT, 15/32 (46.9%)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKIN, Acute Kidney Injury Network; CRRT, continuous renal replacement therapy; ICU, intensive care unit; KDIGO, Kidney Disease Improving Global Outcomes; N/A, not available; LVAD, left ventricular assist device; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; RRT, Renal replacement therapy; UNOS, United Network for Organ Sharing; USA, United States of America.

medicines-06-00108-t002_Table 2

###### 

Included studies in this analysis of AKI associated mortality risk in patients undergoing cardiac transplantation.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                           Year   OR for Mortality                      Confounder Adjustment
  --------------------------------------------------------------- ------ ------------------------------------- ---------------------------------------------------------------------------------------------------------------------
  Ouseph et al. \[[@B31-medicines-06-00108]\]                     1998   1-year mortality\                     None
                                                                         RRT: 16.67 (2.86--97.09)              

  Steven et al. \[[@B33-medicines-06-00108]\]                     2004   0/6 in RRT vs 5/50 (10%) in non-RRT   None

  Wyatt et al. \[[@B34-medicines-06-00108]\]                      2004   Hospital mortality\                   Age, sex, race, DM, transplant center
                                                                         AKI, 3.97 (0.95--16.48)\              
                                                                         RRT, 8.96 (1.75--45.80)               

  Odim et al. \[[@B35-medicines-06-00108]\]                       2006   Hospital mortality\                   None
                                                                         RRT, 17.59 (9.43--32.80)              

  Boyle et al. \[[@B36-medicines-06-00108]\]                      2006   Hospital mortality\                   None
                                                                         RRT, 70.20 (29.71--165.82)            

  Escoresca Ortega et al. \[[@B37-medicines-06-00108]\]           2010   AKI, 1.70 (0.46--6.34)\               None
                                                                         RRT, 3.39 (0.94--12.17)               

  De Santo et al. \[[@B39-medicines-06-00108]\]                   2011   Hospital mortality\                   Preoperative GFR, infection, graft failure
                                                                         AKI, 11.25 (2.81--45.04)\             
                                                                         1-year mortality\                     
                                                                         AKI, 4.25 (1.41--12.79)               

  Arnaoutakis et al. \[[@B40-medicines-06-00108]\]                2012   90-day mortality\                     None
                                                                         RRT, 14.51 (8.84--23.82)              

  Türker et al. \[[@B41-medicines-06-00108]\]                     2013   AKI, 1.56 (0.34--7.06)                None

  Crudele et al. \[[@B42-medicines-06-00108]\]                    2013   Mortality\                            Recipient age, troponin, reoperation, ischemia duration, HLA mismatch
                                                                         AKI, 3.597 (0.95--13.62)              

  Fortrie et al. \[[@B8-medicines-06-00108]\]                     2016   Hospital mortality\                   Age, urgency status on waiting list, RV failure, reoperation, primary graft failure, other transplant complications
                                                                         AKI, 2.27 (0.78--6.59)\               
                                                                         RRT, 4.43 (1.54--12.70)\              
                                                                         1-year mortality\                     
                                                                         AKI, 2.25 (0.93--5.44)\               
                                                                         RRT, 2.75 (1.13--6.63)                

  Tjahjono et al. \[[@B20-medicines-06-00108]\]                   2016   AKI, 3.15 (0.97--10.22)               None

  Schiferer et al. \[[@B45-medicines-06-00108]\]                  2016   1-year mortality\                     None
                                                                         RIFLE AKI, 1.86 (1.01--3.45)\         
                                                                         RRT, 3.71 (1.94--7.07)                

  Hošková et al. \[[@B23-medicines-06-00108]\]                    2016   30-day mortality\                     None
                                                                         AKI, 4.72 (0.75--29.76)\              
                                                                         1-year mortality\                     
                                                                         AKI, 1.52 (0.42--5.46)                

  Giglio Canelhas de Abreu et al. \[[@B47-medicines-06-00108]\]   2017   AKI, 2.83 (0.91--8.78)                Hemoglobin, creatinine, intubation duration, INTERMACS score

  Romeo et al. \[[@B19-medicines-06-00108]\]                      2018   Hospital mortality\                   Age, diabetes, bypass time
                                                                         16/81 in AKI vs 0/31 in no AKI\       
                                                                         RRT, 44.69 (9.09--219.77)\            
                                                                         1-year mortality\                     
                                                                         AKI, 4.44 (0.97--20.36)\              
                                                                         RRT, 6.79 (2.25--20.52)               

  Gašparović et al. \[[@B49-medicines-06-00108]\]                 2018   3-month mortality\                    None
                                                                         RRT, 42.84 (13.07--140.39)            

  Guven et al. \[[@B53-medicines-06-00108]\]                      2018   Hospital mortality\                   None
                                                                         AKI, 3.24 (1.13--9.30)\               
                                                                         1-year mortality\                     
                                                                         AKI, 2.1806 (1.00--4.74)\             
                                                                         RRT, 2.82 (1.28--6.24)                

  García-Gigorro et al. \[[@B18-medicines-06-00108]\]             2018   Hospital mortality\                   Acute right ventricular failure, primary graft failure
                                                                         AKI, 4.84 (1.98--11.84)\              
                                                                         RRT, 11.03 (4.08--29.8)               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; GFR, glomerular filtration rate; HLA, human leukocyte antigen; RV, right ventricular.
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###### 

Reported Risk Factors for AKI among Patients Undergoing Cardiac Transplantation.

  Risk Factors for AKI
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Preoperative risk factors** Higher preoperative serum creatinine or CKD \[[@B8-medicines-06-00108],[@B19-medicines-06-00108],[@B36-medicines-06-00108],[@B43-medicines-06-00108],[@B51-medicines-06-00108]\]Lower serum albumin level \[[@B36-medicines-06-00108]\]Diabetes mellitus \[[@B36-medicines-06-00108],[@B43-medicines-06-00108]\]Increased donor age \[[@B38-medicines-06-00108]\]Older age \[[@B19-medicines-06-00108],[@B41-medicines-06-00108],[@B52-medicines-06-00108]\]Higher BMI \[[@B8-medicines-06-00108]\]Hypertension \[[@B46-medicines-06-00108]\]Higher Logistic EuroSCORE \[[@B18-medicines-06-00108]\]Sepsis \[[@B46-medicines-06-00108]\]Liver disease \[[@B46-medicines-06-00108]\]Elevated troponin I \[[@B39-medicines-06-00108]\]Previous cardiac operation \[[@B39-medicines-06-00108]\] **Perioperative/Postoperative risk factors** Increased cardiopulmonary bypass time \[[@B20-medicines-06-00108],[@B36-medicines-06-00108]\]Increased surgery time \[[@B50-medicines-06-00108]\]Administration of intravenous cyclosporin immediately post-operation, use of cyclosporine \[[@B38-medicines-06-00108],[@B41-medicines-06-00108]\]; supratherapeutic tacrolimus trough concentration \[[@B50-medicines-06-00108]\]Increased graft ischemic time \[[@B39-medicines-06-00108]\]Lower hemoglobin/hematocrit/platelet count \[[@B52-medicines-06-00108]\]; higher blood and cryoprecipitate transfusions \[[@B20-medicines-06-00108],[@B39-medicines-06-00108]\]Post-operative bleeding with subsequent surgical re-exploration \[[@B18-medicines-06-00108],[@B20-medicines-06-00108]\]Postoperative RV failure \[[@B8-medicines-06-00108],[@B18-medicines-06-00108]\]RVAD/VA ECMO after heart transplant \[[@B23-medicines-06-00108]\]Mechanical ventilation \[[@B46-medicines-06-00108]\]Increased peripheral vascular resistance \[[@B19-medicines-06-00108]\]Nadir oxygen delivery \< 300 mL/min/m^2^ \[[@B51-medicines-06-00108]\]Higher right atrial pressure, lower pulmonary artery pulsatility index \[[@B53-medicines-06-00108]\]Cardiac tamponade \[[@B18-medicines-06-00108]\]

Abbreviations: CKD, chronic kidney disease; BMI, body mass index; RVAD, right ventricular assist device; VA ECMO, venoarterial extra-corporal membrane oxygenation.
